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AbstrAct
Objective To investigate the prevalence and associated 
cardiovascular risk factors 6 years after hyperglycemia first 
detected in pregnancy (HFDP) in Cape Town, South Africa.
Research design and methods Data were collected 
during the index pregnancy from all women diagnosed with 
HFDP at a major referral hospital in Cape Town. Participants 
were evaluated 6 years later using a cross- sectional study. 
At follow- up participants had a 75 g oral glucose tolerance 
test, fasting lipogram, blood pressure and anthropometric 
measurements, and a fieldworker administered the 
questionnaire. We used the Adult Treatment Panel III criteria 
for the diagnosis of metabolic syndrome and individual 
risk factors. Insulin resistance was assessed using the 
homeostatic model of insulin resistance.
Results At follow- up 220 women were reviewed. Their 
mean age at follow- up was 37.2 (SD 6.0) years. The 
prevalence of cardiovascular disease (CVD) risk factors was 
60.9% (95% CI 54.3 to 67.2) for metabolic syndrome, 75% 
(95% CI 65.9 to 82.3) for insulin resistance, 62.3% (95% 
CI 55.6 to 68.5) for dysglycemia, 41.4% (95% CI 35.0 to 
48.0) for raised blood pressure, and 74.6% (95% CI 683 to 
79.9) for dyslipidemia. Women with diabetes in pregnancy 
compared with those with gestational diabetes during the 
index pregnancy had a higher prevalence of metabolic 
syndrome (74.3% vs 54.7%, p=0.010) and dysglycemia 
(88.6% vs 50.0%, p<0.001) at follow- up. Lower school 
education attainment, having a subsequent pregnancy, waist 
circumference at follow- up, and fasting blood glucose at 
HFDP diagnosis were associated with metabolic syndrome.
Conclusion We found a high prevalence of CVD risk factors 
in South African women within 6 years of HFDP, which 
highlights the need to develop and evaluate interventions 
optimizing the cardiometabolic health of this vulnerable 
group. The main limitations of our research are the lack of a 
comparative group of women without HFDP and that we did 
not assess for CVD risk factors before HFDP.
BaCkgROund
Non- communicable diseases (NCDs) are the 
leading causes of illness and death worldwide. 
They accounted for 71% of overall mortality, 
in 2016, while cardiovascular diseases (CVD) 
and diabetes were responsible for almost half 
(47.6%) of the NCD burden.1 The majority 
of premature deaths from NCDs (85%) 
occur in low- income to middle- income coun-
tries,1 where health systems are struggling to 
cope with the concurrent problems of infec-
tious diseases and emerging NCDs. In South 
Africa, the rapidly increasing prevalence of 
NCDs contributes to the multiple burden of 
disease, comprising tuberculosis and HIV, 
ongoing malnutrition, and high maternal 
and child mortality.2 3 Diabetes and CVD have 
been the second and third leading causes of 
death in the country since 2014,4 highlighting 
the need to prioritize their prevention. One 
prevention strategy could be through identi-
fication of high- risk populations and offering 
tailored interventions.
Recent South African epidemiologic 
surveys show that at least a quarter of preg-
nant women (26%) have hyperglycemia 
first detected in pregnancy (HFDP),5 while 
almost 10% have gestational diabetes mellitus 
(GDM).6 This may increase their risk for 
significance of this study
What is already known about this subject?
 ► Women with a history of hyperglycemia first detect-
ed in pregnancy (HFDP), which includes gestational 
diabetes, may have a higher risk for cardiovascular 
disease (CVD), although to our knowledge there are 
no data from Africa.
What are the new findings?
 ► In this study, we found a high prevalence of CVD risk 
factors 6 years after HFDP in women with a mean 
age of 37 years in Cape Town, South Africa.
How might these results change the focus of 
research or clinical practice?
 ► Given their relatively young age, there is a need for 
research which investigates innovative interventions 
to encourage women to change their lifestyles after 
HFDP, to reduce the risk of CVD.
 ► These women may require frequent screening for 
CVD risk factors after pregnancy.
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early CVD. However, as the risk factor- based screening 
currently being used in South Africa is suboptimal, 
a significant proportion of pregnant women are not 
screened for HFDP.5 7 Until recently, GDM was defined 
as HFDP with a postpartum return to normalcy in many 
guidelines. Further, the criteria used for the diagnosis of 
GDM have varied widely in different countries. However, 
the WHO 2013 guidelines,8 which were largely based 
on the results of the Hyperglycemia and Adverse Preg-
nancy Outcomes Study,9 and the recommendations of 
the International Association of Diabetes and Pregnancy 
Study Groups10 have been adopted by many regional 
and national bodies. These WHO guidelines include the 
adoption of lower fasting glucose cut- offs and the distinc-
tion between GDM and diabetes in pregnancy (DIP), 
where blood glucose concentrations are diagnostic of 
type 2 diabetes mellitus.
Meta- analyses have shown that women with a history of 
GDM (although these studies also included women with 
DIP, according to the WHO 2013 criteria) have double 
the risk for overall CVD11 12 and coronary artery disease 
in the long term12 and four times the risk for metabolic 
syndrome,13 compared with women with normoglycemic 
pregnancies.13 There may be population differences in 
the association between GDM and metabolic syndrome, 
as Asian studies did not show the association seen with 
other populations. Although metabolic syndrome’s utility 
as a clinical entity is debatable, it represents a constella-
tion of risk factors for CVD, with possible common patho-
physiology and common environmental risk factors. 
Insulin resistance, thought to be central in the develop-
ment of metabolic syndrome,14 is also associated with 
beta- cell deterioration during the immediate post- HFDP 
period15 and consequent progression to type 2 diabetes.16
To the best of our knowledge, there are no published 
studies on the intermediate and long- term burden of 
CVD in African women post- HFDP, despite the increasing 
understanding of the critical role women of childbearing 
age play in the possible intergenerational transmission of 
and prevention of CVD risk. The aim of this study was 
to describe the prevalent metabolic syndrome, insulin 
resistance and individual CVD risk factors (raised blood 
pressure, dysglycemia, dyslipidemia, raised waist circum-
ference, and overweight and obesity) and their risk 
factors in women 6 years post- HFDP in Cape Town, South 
Africa. We also compared the prevalence of metabolic 
syndrome and individual CVD risk factors between GDM 
and DIP groups, after reclassifying HFDP, post hoc, using 
modified WHO 2013 criteria.
MeTHOds
All women diagnosed and treated for GDM at a major 
tertiary referral hospital in Cape Town, South Africa, 
between 1 August 2010 and 30 September 2011, were 
eligible for a cross- sectional follow- up study 6 years later. At 
the time of the pregnancy, GDM was defined as any glucose 
intolerance first detected in pregnancy according to the 
2008 National Institute for Health and Care Excellence 
guidelines (fasting glucose >5.6 mmol/L and oral glucose 
tolerance test (OGTT) 2- hour glucose ≥7.8 mmol/L).17 
We retrospectively classified these women using modified 
WHO 2013 criteria as HFDP, since the criteria used at the 
time of the pregnancy included women with GDM and 
those with DIP, and then grouped the participants into 
GDM (fasting glucose 5.6–6.9 mmol/L and OGTT 2- hour 
glucose 7.8–11.0 mmol/L) and DIP (fasting glucose 
≥7.0 mmol/L and OGTT 2- hour glucose ≥11.1 mmol/L). 
Between 1 May 2016 and 30 March 2017, the women were 
invited for follow- up assessment via telephone, postal 
mail and home visits. Women with known type 1 or type 2 
diabetes were excluded during the pregnancy and preg-
nant women were excluded from the follow- up study.
study procedures
Pregnancy- related data were collected during the index 
pregnancy, as part of routine clinical care, but women, 
as part of this study, were not assessed for the following 
CVD risk factors as they are affected by the pregnancy: 
central obesity, raised blood pressure and dyslipidemia. 
At follow- up, participants were invited to come for assess-
ment at the research unit.
Trained fieldworkers administered a questionnaire 
(adapted from the WHO STEPWise survey question-
naire18) to collect sociodemographic, breastfeeding and 
potential risk factor information. The following sections 
of the core WHO STEPWise questionnaire were used: 
history of chronic illnesses, physical measurements, and 
alcohol and tobacco use, in addition to questions on 
reproductive health. Physical activity was assessed using 
the modified Global Physical Activity Questionnaire 
(GPAQ). Average breastfeeding length was calculated as 
the total months a participant breast fed divided by the 
number of children she breast fed.
The fieldworkers carried out anthropometric measure-
ments (height, weight, waist and hip circumference) using 
standard methods.18 Each measurement was repeated 
three times, at least 5 min apart, and the average was 
calculated. Height was measured to the nearest 0.1 cm 
using a wall- mounted stadiometer. Weight was measured 
to the nearest 0.1 kg, with the participant putting on light 
clothing, without shoes, on a bathroom scale placed on a 
hard flat floor. Waist circumference was measured to the 
nearest 0.1 cm using a flexible tape, with the participant 
having one layer of clothing, at the midpoint between 
the lower costal margin and the level of the superior iliac 
crests. Hip circumference was measured to the nearest 
0.1 cm at the widest part of the hip, with a flexible tape 
held horizontally. Each participant had three blood pres-
sure measurements 5 min apart while seated comfortably, 
using an Omron automated blood pressure monitor 
(Omron 711; Omron Healthcare, Hamburg, Germany). 
The average of the last two readings was used in analyses.
Each participant underwent a 75 g OGTT (unless 
already diagnosed with diabetes) after fasting for 8–10 
hours. Fasting blood was drawn for glucose, insulin 
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Figure 1 Study flow chart.
and lipids. In addition, blood was drawn at 2 hours for 
glucose. Participants on treatment for high blood pres-
sure, raised blood lipids and diabetes were not required 
to give samples or take measurements for the respective 
conditions. The samples were kept on ice until centrifu-
gation within 4 hours of collection and the aliquots stored 
at −80°C until biochemical analysis.
Outcomes
The outcomes were metabolic syndrome (having ≥3 CVD 
risk factors) and individual CVD risk factors (dysglycemia, 
raised blood pressure, dyslipidemia and central obesity), 
defined according to a modified National Cholesterol 
Education Program Adult Treatment Panel III.19 Raised 
blood pressure was defined as either diastolic blood pres-
sure above 85 mm Hg and/or systolic blood pressure 
above 130 mm Hg. Dyslipidemia was defined as either 
triglycerides ≥1.7 mmol/L and/or high- density lipopro-
tein cholesterol ≤1.30 mmol/L. Dysglycemia was defined 
as fasting plasma glucose ≥5.6 mmol/L. Body mass index 
(BMI) was grouped according to WHO criteria for under-
weight (<18.5 kg/m2), normal weight (18.5–24.9 kg/m2), 
overweight (25–29.9 kg/m2), obese (30–39.9 kg/m2) and 
morbidly obese (>40 kg/m2), while a waist circumfer-
ence cut- off of ≥88 cm was used for central obesity.20 We 
assessed insulin resistance using the homeostatic model 
assessment of insulin resistance using a cut- off of 1.95, as 
used in a previous study in obese South African women.21 
Participants with known diabetes at the time of follow- up 
were excluded from insulin resistance assessment.
Biochemistry and laboratory analyses
Plasma glucose was measured using the hexokinase 
method on a Randox RX Daytona Chemistry Analyzer. 
Enzymatic colorimetric assays were used to measure 
triglycerides, total cholesterol and high- density lipopro-
tein cholesterol using the Roche Modular Auto Analyzer, 
while low- density lipoprotein cholesterol was calculated 
using direct methods. Coefficients of variation calculated 
from running 40 separate samples in duplicate were 3.0% 
for glucose, 3.1% for cholesterol, 3.1% for triglycerides 
and 3.4% for insulin.
statistical data analysis
Stata V.15 statistical software22 was used for all analyses, 
with p<0.05 for significance and 95% CI reported for esti-
mates, where appropriate. Means and SDs are presented 
for normally distributed measured data, medians and 
IQRs for non- normally distributed data, and frequencies 
and proportions for categorical variables. Comparisons of 
participants with metabolic syndrome and those without 
were done using the χ2 test for categorical data and inde-
pendent groups t- test (normally distributed measured 
data) or Wilcoxon rank- sum test (for measured data that 
were not normally distributed). The prevalence of CVD 
risk factor was calculated as the proportion of partici-
pants with the outcome over the total assessed.
To explore factors associated with metabolic syndrome, 
multiple variable logistic regression was used. Pregnancy- 
related variables entered into the logistic regression 
models were fasting and 2- hour OGTT glucose levels 
at HFDP diagnosis and type of treatment during HFDP. 
Variables measured at follow- up included in the logistic 
regression were socioeconomic characteristics (age, 
ethnicity, education and employment), anthropometry 
(waist and hip circumference, BMI), family history of 
high blood pressure, reproductive health factors (subse-
quent pregnancy (yes/no) and average breastfeeding 
length in months), total minutes of physical activity per 
week from the modified GPAQ, and smoking (current 
smoker or not). Stopping alcohol due to health reasons 
and BMI at pregnancy booking were not included in the 
multiple logistic regression due to missing data.
For each of the following individual CVD risk factors, 
we explored risk factors using multiple variable logistic 
regression separately: raised blood pressure, dysglycemia, 
dyslipidemia and insulin resistance. Bonferroni adjust-
ment was used to compensate for multiple testing by 
multiplying the individual p values by the total number 
of outcomes (four). For insulin resistance, only the 108 
participants who had no diabetes at follow- up and had 
fasting insulin measurements were included.
Logistic regression model diagnostics included 
linearity assumption testing using the Lowess graph, 
multicollinearity testing using variance inflation factors 
(VIF), using a a cut- off of the square of the VIF above 
4, model specification testing using the C- statistic link-
test (_hatsq), and confirmation of the fit of the model 
using the Hosmer- Lemeshow goodness- of- fit test. The 
area under the receiving operating characteristic (ROC) 
curve and k- fold cross- validation (k=10) were used for 
model validation. The study is reported according to the 
Strengthening the Reporting of Observational Studies in 
Epidemiology23 guidelines.
ResulTs
Two hundred and twenty participants (44.2%) were 
followed up (figure 1). There were no differences in any 
sociodemographic characteristics during the index HFDP 
in those followed up compared with the women lost to 
follow- up. However, compared with participants lost to 
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follow- up, participants assessed at follow- up had higher 
median BMI at booking (34.6 (IQR 28.8–41.4) kg/m2 vs 
32.7 (IQR 27.6–38.4) kg/m2, respectively) but lower median 
2- hour OGTT glucose concentrations at HFDP diagnosis 
(9 (IQR 8.2–10) mmol/L vs 12 (IQR 11.2–12.8) mmol/L, 
respectively) (online supplementary table 1).
Table 1 shows the characteristics of the participants 
during the pregnancy and at follow- up, as well as a compar-
ison by metabolic syndrome status. When the HFDP was 
classified retrospectively using modified WHO 2013 
criteria, 70 of the 220 participants were classified as DIP, 
while the remaining 150 women were classified as GDM.
At booking of the index pregnancy, the participants’ 
mean age was 30.8 (SD 5.9) years, and at follow- up 
37.2 (SD 6.0) years. The majority (142, 65.4%) were of 
mixed ancestry. Participants with metabolic syndrome at 
follow- up had significantly higher mean BMI and age at 
booking of the index pregnancy and higher fasting and 
OGTT 1- hour and 2- hour blood glucose concentrations 
at diagnosis of HFDP, compared with those without meta-
bolic syndrome (table 1).
One hundred and five (47.7%) participants had 
diabetes at follow- up and were not assessed for insulin 
resistance. Compared with participants without meta-
bolic syndrome, those with metabolic syndrome had a 
significantly higher BMI and were significantly less likely 
to have tertiary education (table 1). The anthropometric 
and biochemical characteristics of the participants at 
follow- up are shown in online supplementary table 2.
Prevalence of CVd risk factors, metabolic syndrome and 
insulin resistance at follow-up, and comparison between dIP 
and gdM groups
The prevalence of metabolic syndrome was 60.9% (95% 
CI 54.3 to 67.2), and the prevalence of the individual CVD 
risk factors was 75.0% (95% CI 65.9 to 82.3) for insulin 
resistance, 90.4% (95% CI 85.6 to 93.7) for waist circum-
ference ≥88 cm, 74.6% (95% CI 68.3 to 79.9) for dyslip-
idemia, 62.3% (95% CI 55.6 to 68.5) for dysglycemia, 
47.3% (95% CI 40.7 to 53.9) for obesity, 21.8% (95% 
CI 16.8 to 27.8) for morbid obesity and 41.4% (95% CI 
35.0 to 48.0) for raised blood pressure (figure 2, online 
supplementary table 3). The proportions of participants 
already diagnosed with CVD risk factors were as follows: 
25.0% for diabetes, 20.0% for hypertension and 10.9% 
for dyslipidemia (table 1). Compared with women with 
GDM, women with DIP had higher prevalence of both 
metabolic syndrome (74.3% vs 54%, p=0.010) and dysgly-
cemia (88.6% vs 50%, p<0.001), but the proportions with 
insulin resistance and the remaining CVD risk factors did 
not differ significantly between the two groups (online 
supplementary table 3).
Factors associated with metabolic syndrome and individual 
CVd risk factors at follow-up: multiple variable logistic 
regression
After multiple variable logistic regression, fasting blood 
glucose at HFDP diagnosis (OR 1.5, 95% CI 1.1 to 2.0, 
p=0.006), having secondary and matric education, 
compared with tertiary education (OR 2.5, 95% CI 1.3 to 
9.4, p=0.014), having a subsequent pregnancy (OR 0.4, 
95% CI 0.2 to 0.9), and waist circumference (OR 1.1, 
95% CI 1.0 to 1.1, p<0.001) were independently associ-
ated with metabolic syndrome (figure 3).
Online supplementary tables 4A,B show the multiple 
variable logistic regression of factors associated with the 
individual CVD risk factors. Waist circumference was 
associated with raised blood pressure (OR 1.1, 95% CI 
1.0 to 1.1, p=0.036), dyslipidemia (OR 1.1, 95% CI 1.0 to 
1.1, p=0.32) and dysglycemia (OR 1.1, 95% CI 1.0 to 1.1, 
p<0.001), while hip circumference was associated with 
dyslipidemia (OR 0.9, 95% CI 0.9 to 1.0, p=0.032) and 
dysglycemia (OR 0.9, 95% CI 0.9 to 1.0, p=0.044). Being 
employed was associated with raised blood pressure (OR 
0.3, 95% CI 0.2 to 0.7, p=0.008).
logistic regression diagnostics and validation: metabolic 
syndrome outcome
The Lowess graph indicated an acceptable linear rela-
tionship. Hip circumference (VIF 4.39) was removed 
from the initial model as it was collinear with waist 
circumference (VIF 3.95) and BMI at follow- up (VIF 
4.78). The link function was correctly specified (p=0.630) 
and the Hosmer- Lemeshow goodness- of- fit test showed 
that the model fit was acceptable (p=0.444). A few influ-
ential cases were identified by plotting residual against 
predicted probabilities, although sensitivity analysis 
showed no differences in model estimates when these 
cases were omitted. The model validation was reasonable, 
the area under the ROC curve was 0.907, and the cross- 
field validation with k=10 folds showed pseudo- R2 values 
which ranged from 0.21 to 0.49.
dIsCussIOn
In this study of women with a mean age of 37 years and 
a 6- year history of HFDP, there was a high prevalence of 
metabolic syndrome as well as of the individual compo-
nents, with very low proportions of the participants being 
aware of their disease status. When the HFDP was catego-
rized according to criteria that approximated the WHO 
2013 HFDP diagnostic criteria, women with DIP had a 
higher prevalence of both metabolic syndrome and dysgly-
cemia compared with those classified as GDM. A high waist 
circumference, lower education attainment, having had 
a subsequent pregnancy at follow- up and fasting blood 
glucose at HFDP diagnosis were all independently associ-
ated with metabolic syndrome at follow- up. An increase in 
waist circumference was associated with risk of raised blood 
pressure, dyslipidemia and dysglycemia.
To our knowledge, this is the first to investigate the 
prevalence of metabolic syndrome, insulin resistance and 
individual CVD risk factors in African women post- HFDP. 
As different study designs, heterogeneous definitions 
of GDM and different lengths of follow- up complicate 
comparison of our findings with international data, we 
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Table 1 Characteristics of participants, by the presence or absence of metabolic syndrome
Overall
Metabolic syndrome 
at follow- up
No metabolic 
syndrome at 
follow- up (<3 CVD 
risk factors) P value
n 220 134 86
Variables measured at baseline
  Age (years) Mean (SD) 30.8 (5.9) 32.0 (5.7) 29.0 (5.7) <0.001
  BMI at booking (kg/m2) Mean (SD) 34.2 (8.2) 36.2 (7.3) 32.2 (8.5) <0.001
  BMI categories at booking, 
n (%)
Normal 31 (14.5) 7 (5.2) 24 (27.9) <0.001
Overweight 38 (17.8) 17 (12.7) 21 (24.4)
Obese 96 (44.9) 76 (56.7) 26 (30.2)
Morbidly obese 49 (22.9) 34 (25.4) 15 (17.4)
  HFDP type, n (%) DIP 70 (31.8) 18 (22.1) 52 (38.8) 0.01
GDM 150 (68.2) 67 (77.9) 82 (61.2)
  Insulin treatment for HFDP, 
n (%)
Yes 52 (23.6) 39 (29.1) 13 (15.1) 0.017
OGTT at HFDP diagnosis
  Fasting blood glucose 
(mmol/L)
Median (IQR) 5.8 (5.1–6.7) 6.1 (5.4–7.1) 5.5 (4.9–6.3) <0.001
  1- hour blood glucose 
(mmol/L)
Median (IQR) 10.4 (9.2–11.6) 10.6 (9.5–11.9) 10.0 (8.7–11.2) 0.006
  Insulin treatment for HFDP, 
n (%)
Yes 52 (23.6) 39 (29.1) 13 (15.1) 0.017
  2- hour glucose (mmol/L) Median (IQR) 9.0 (8.3–10.5) 9.1 (8.4–1.0) 8.8 (8.2–9.6) 0.022
Variables measured at follow- up
  Follow- up time (years) Median (IQR) 6.1 (2.8–11.0) 5.6 (1.1–9.5) 6.9 (4.8–12.8) 0.002
  Education, n (%) Tertiary 30 (13.6) 9 (6.7) 21 (24.4) 0.001
Secondary and 
matric
167 (75.9) 109 (81.3) 58 (67.4)
Primary 23 (10.5) 16 (11.9) 7 (8.1)
  Employed, n (%) Yes 108 (49.1) 57 (42.5) 51 (59.3) 0.015
  Marital status, n (%) Married 141 (64.1) 86 (64.2) 55 (64.0) 0.832
  Family history, n (%) Diabetes 169 (76.8) 103 (76.9) 66 (76.7) 0.983
Hypertension 156 (70.9) 98 (73.1) 58 (67.4) 0.364
Stroke and heart 
attack
96 (43.6) 59 (44.0) 37 (43.0) 0.883
  Stopped drinking alcohol for 
health reasons, n (%)
Yes 14 (6.4) 10 (7.5) 4 (4.7) 0.486
  Current smoker, n (%) Yes 64 (29.1) 37 (27.6) 27 (31.4) 0.547
  GPAQ total physical activity 
(min)
Median (IQR) 450 (110–1405) 420 (177.5–1502.5) 375 (90–1280) 0.274
  Subsequent pregnancy, n 
(%)
Yes 58 (26.4) 32 (23.9) 26 (30.2) 0.297
  Average breastfeeding 
length (months)
Median (IQR) 6 (1–18) 8 (1–18) 6 (1–12) 0.332
  Follow- up BMI (kg/m2) Mean (SD) 34.9 (8.7) 36.8 (8.3) 32.0 (8.6) <0.001
  Weight gain (kg) Median (IQR) 2.0 (−4.6 to 9.0) 1.5 (−7.0 to 9.0) 3.3 (−3.1 to 7.9) 0.511
Continued
 o
n
 April 8, 2020 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000740 on 27 November 2019. Downloaded from 
6 BMJ Open Diab Res Care 2019;7:e000740. doi:10.1136/bmjdrc-2019-000740
Cardiovascular and Metabolic Risk
Overall
Metabolic syndrome 
at follow- up
No metabolic 
syndrome at 
follow- up (<3 CVD 
risk factors) P value
  Follow- up BMI categories, 
n (%)
Normal 24 (10.9) 6 (4.5) 18 (20.9) <0.001
Overweight 44 (20.0) 21 (15.7) 23 (26.7)
Obese 104 (47.3) 70 (52.2) 34 (39.5)
Morbidly obese 48 (21.8) 37 (27.6) 11 (12.8)
  Waist circumference (cm) Mean (SD) 110.5 (17.6) 115.6 (16.9) 102.3 (15.6) <0.001
  Hip circumference (cm) Mean (SD) 117.3 (16.1) 119.3 (15.7) 113.9 (16.4) 0.008
  Self- reported comorbidities, 
n (%)
Diabetes 55 (25.0) 45 (33.6) 10 (11.6) <0.001
Hypertension 44 (20.0) 42 (31.3) 2 (2.3) <0.001
Dyslipidemia 24 (10.9) 22 (16.4) 2 (2.3) 0.001
BMI, body mass index; CVD, cardiovascular disease; DIP, diabetes in pregnancy; GDM, gestational diabetes mellitus; GPAQ, Global Physical 
Activity Questionnaire; HFDP, hyperglycemia first detected in pregnancy; OGTT, oral glucose tolerance test.
Table 1 Continued
Figure 2 Prevalence of cardiovascular disease risk factors and insulin resistance 6 years after hyperglycemia first detected in 
pregnancy. BMI, body mass index; HOMA- IR, homeostatic model assessment of insulin resistance.
have attempted to compare our findings with studies that 
used criteria for GDM similar to ours as well as a similar 
duration of follow- up. Our prevalence estimates are 
similar to data from India, where the reported metabolic 
syndrome prevalence was 55%,24 dysglycemia prevalence 
was 68%25 and dyslipidemia was 71%.24 On the other 
hand, our prevalence estimates are much higher than 
those reported from other countries. In China, the prev-
alence of metabolic syndrome was 7.5%,26 in Brazil the 
prevalence of dysglycemia was 39.4%,27 and in Ireland 
the prevalence of dyslipidemia was 25%.28 We found only 
a single study that assessed insulin resistance28 to date, 
which reported a prevalence of 33.6%, which is less than 
half of the prevalence in our study.
We were unable to find studies that compared CVD risk 
factors at follow- up between women with DIP and those 
with GDM. Given that the DIP group may include undiag-
nosed type 2 diabetes cases, this group’s higher prevalence 
of dysglycemia compared with that in the GDM group is 
expected. The former’s higher metabolic syndrome preva-
lence could be partly explained by the higher proportion 
of women with dysglycemia as well as diabetes- associated 
dyslipidemia. Thus, early intervention and screening for 
CVD risk factors for women with DIP are warranted.
Our study has several limitations. A major limitation 
was the lack of a control group. Despite this, we were able 
to use prevalence estimates based on the same criteria for 
our outcomes of interest in women of childbearing age 
from population surveys in Cape Town. In these studies, 
the prevalence of metabolic syndrome ranged from 
9.9%21 to 43%,29 the prevalence of raised blood pressure 
was 19.9%,21 the prevalence of dysglycemia was 2.2%,30 
17.9%31 and 32.6%,32 the prevalence of dyslipidemia was 
46%, and the prevalence of insulin resistance in obese 
women was 38%.33 Thus, our findings suggest higher 
prevalences of CVD risk factors in our study population 
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Figure 3 Multiple variable logistic regression for factors 
associated with metabolic syndrome. Model statistics 
(observations: 218, p value: 0.000, pseudo- R2: 0.25). BP, 
blood pressure; BMI, body mass index; HFDP, hyperglycemia 
first detected in pregnancy; PA, physical activity; T2DM, type 
2 diabetes mellitus.
when compared with population- based survey data of 
women of childbearing age in Cape Town. Interventions 
to reduce risk of CVD risk factors and consequent CVD 
should be considered. This has the potential to improve 
more than the mother’s health; it may also reduce the 
risk of hyperglycemia in future pregnancies and subse-
quently reduce the potential for intergenerational trans-
mission of CVD risk through fetal programming.34
The first intervention could be integrating CVD risk 
factor screening with the recommended postpartum 
screening for diabetes. Currently, the recommended 6- week 
postpartum screening for diabetes has a poor uptake, in 
keeping with international trends. In our setting, innova-
tive solutions to the various health system and sociodemo-
graphic barriers may be required to improve uptake.35 The 
very low number of women who were aware that they had 
CVD risk factors and on treatment is a cause for concern. 
Combining the postpartum care of the mother with that 
of the baby may offer a window to both screen for CVD 
risk factors and provide an opportunity to engage with the 
mother to promote change in her modifiable CVD risk 
factors. This postpartum review may need to be extended 
to include obese women, as our data showed that high 
waist circumference was associated with CVD risk factors 
at follow- up. However, this will have health system impli-
cations because of the high prevalence of obesity in South 
African women of childbearing age.36 The high prevalence 
of obesity has been attributed to changes in diet and phys-
ical activity patterns among urban- dwelling South African 
women.36 Lifestyle change should therefore be part of a 
holistic package to prevent CVD risk in these women while 
at the same time reducing the consequent cardiometabolic 
disease risk in future offspring.
A further limitation of our study is that we were only 
able to assess 44% of women at follow- up, due to the 
population being highly mobile. The rate of follow- up 
is comparable with studies from other low- income to 
middle- income countries.37 38 As we followed up fewer 
women with DIP, we may have underestimated the prev-
alence of both metabolic syndrome and dysglycemia. 
On the other hand, the women who we were able to 
follow up had a higher BMI by 2 units compared with 
those we were not able to follow- up, thus overesti-
mating the prevalences of the CVD risk factors. Finally, 
as we did not assess the presence of the CVD risk factors 
during the index pregnancy, it is difficult to properly 
estimate the effect of HFDP on the risk of metabolic 
syndrome and its components.
COnClusIOn
Given the considerable and growing burden of diabetes 
and CVD in South Africa, the high prevalence of CVD risk 
factors found in relatively young African women within 6 
years of a previous HFDP highlights the need to develop 
and evaluate interventions optimizing the cardiometa-
bolic health of this group.
author affiliations
1Chronic Disease Initiative for Africa, Faculty of Medicine and Health Sciences, 
University of Cape Town, Cape Town, Western Cape, South Africa
2SAMRC/Wits Developmental Pathways for Health Research Unit, Department of 
Paediatrics, University of the Witwatersrand, Parktown, Gauteng, South Africa
3Population Medicine, College of Medicine, Qatar University, Doha, Qatar
4School of Human Development and Health, and NIHR Southampton Biomedical 
Research Centre, University of Southampton, Southampton, UK
acknowledgements We thank Ms Chantal Stuart (administration and logistics) 
and Ms Siphokazi Khonkwane (fieldwork) at the Chronic Disease Initiative for Africa 
for their support during data collection at follow- up. We acknowledge Dr Hetta van 
Zyl for collecting pregnancy- related data from participants and Professors Krisela 
Steyn and Christina Zarowsky for help during the conception of the research.
Contributors Conceptualization: TC, SAN, NSL. Data curation: TC. Formal analysis: 
TC, SAN, NSL. Funding acquisition: SAN, NSL. Investigation: TC. Methodology: 
TC, SAN, NSL. Project administration: TC. Resources: SAN, NSL. Software: TC. 
Supervision: SAN, NSL. Validation: TC. Writing of original draft: TC. Review and 
editing: TC, SAN, NSL.
Funding This research was funded by the Chronic Disease Initiative for Africa. We 
acknowledge funding from the International Development Research Centre (IDRC) 
(fund number: 411592) for TC (under the IINDIAGO project).
Competing interests None declared.
Patient consent for publication Not required.
ethics approval The study was carried out according to the principles of the Helsinki 
Declaration. The study was approved by the Human Research Ethics Committees of 
the University of Cape Town (Ref: 656/2015). Informed consent was obtained from 
all participants. Participants who were found to have either hypertension or diabetes 
were referred for treatment.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCId id
Tawanda Chivese http:// orcid. org/ 0000- 0001- 6621- 6144
 o
n
 April 8, 2020 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000740 on 27 November 2019. Downloaded from 
8 BMJ Open Diab Res Care 2019;7:e000740. doi:10.1136/bmjdrc-2019-000740
Cardiovascular and Metabolic Risk
RefeRences
 1. World Health Organization. Noncommunicable diseases 2016, 2018. 
Available: https://www. who. int/ en/ news- room/ fact- sheets/ detail/ 
noncommunicable- diseases [Accessed 27 Jan 2019].
 2. Kabudula CW, Houle B, Collinson MA, et al. Progression of the 
epidemiological transition in a rural South African setting: findings 
from population surveillance in Agincourt, 1993-2013. BMC Public 
Health 2017;17:424.
 3. Mayosi BM, Benatar SR. Health and health care in South 
Africa — 20 years after Mandela. N Engl J Med Overseas Ed 
2014;371:1344–53.
 4. Statistics South A. P0309.3 - Mortality and causes of death in South 
Africa: Findings from death notification, 2016 2018.
 5. Adam S, Rheeder P. Screening for gestational diabetes mellitus in 
a South African population: prevalence, comparison of diagnostic 
criteria and the role of risk factors. S Afr Med J 2017;107:523–7.
 6. Macaulay S, Ngobeni M, Dunger DB, et al. The prevalence of 
gestational diabetes mellitus amongst black South African women is 
a public health concern. Diabetes Res Clin Pract 2018;139:278–87.
 7. Coetzee A, Mason D, Hall DR, et al. Prevalence and predictive 
factors of early postpartum diabetes among women with 
gestational diabetes in a single- center cohort. Int J Gynecol Obstet 
2018;142:54–60.
 8. World Health Organization. Diagnostic criteria and classification of 
hyperglycaemia first detected in pregnancy 2013.
 9. Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse 
pregnancy outcomes. N Engl J Med 2008;358:1991–2002.
 10. Metzger BE, Gabbe SG, Persson B, et al. International association 
of diabetes and pregnancy study groups recommendations on the 
diagnosis and classification of hyperglycemia in pregnancy. Diabetes 
Care 2010;33:676–82.
 11. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the 
risk of cardiovascular disease in women: a systematic review and 
meta- analysis. Diabetologia 2019;62:905–14.
 12. Li J, Song C, Li C, et al. Increased risk of cardiovascular disease 
in women with prior gestational diabetes: a systematic review and 
meta- analysis. Diabetes Res Clin Pract 2018;140:324–38.
 13. Xu Y, Shen S, Sun L, et al. Metabolic syndrome risk after gestational 
diabetes: a systematic review and meta- analysis. PLoS One 
2014;9:e87863.
 14. Stern MP. Diabetes and cardiovascular disease. The "common soil" 
hypothesis. Diabetes 1995;44:369–74.
 15. Retnakaran R, Qi Y, Ye C, et al. Hepatic insulin resistance is 
an early determinant of declining -cell function in the first year 
postpartum after glucose intolerance in pregnancy. Diabetes Care 
2011;34:2431–4.
 16. Xiang AH, Kjos SL, Takayanagi M, et al. Detailed physiological 
characterization of the development of type 2 diabetes in 
Hispanic women with prior gestational diabetes mellitus. Diabetes 
2010;59:2625–30.
 17. Guidelines Development Group. Management of diabetes from 
preconception to the postnatal period: summary of NICE guidance. 
BMJ 2008;336:714–7.
 18. World Health Organization. Who steps surveillance manual: the who 
stepwise approach to chronic disease risk factor surveillance 2005.
 19. Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults. Executive summary of the third report of the 
National cholesterol education program (NCEP) expert panel on 
detection, evaluation, and treatment of high blood cholesterol in 
adults (adult treatment panel III). JAMA 2001;285:2486–97.
 20. World Health Organization. Waist circumference and waist- hip ratio 
report of a who expert consultation, Geneva, 8–11 December 2008, 
2008. Available: https:// apps. who. int/ iris/ bitstream/ handle/ 10665/ 
44583/ 9789241501491_ eng. pdf? ua=1
 21. Jennings CL, Lambert EV, Collins M, et al. The atypical presentation 
of the metabolic syndrome components in black African women: 
the relationship with insulin resistance and the influence of regional 
adipose tissue distribution. Metabolism 2009;58:149–57.
 22. Stata Crop. College Station (TX). Stata press, 2016.
 23. von Elm E, Altman DG, Egger M, et al. The strengthening the 
reporting of observational studies in epidemiology (STROBE) 
statement: guidelines for reporting observational studies. PLoS Med 
2007;4:e296.
 24. Kale SD, Yajnik CS, Kulkarni SR, et al. High risk of diabetes and 
metabolic syndrome in Indian women with gestational diabetes 
mellitus. Diabet Med 2004;21:1257–8.
 25. Krishnaveni GV, Hill JC, Veena SR, et al. Gestational diabetes 
and the incidence of diabetes in the 5 years following the index 
pregnancy in South Indian women. Diabetes Res Clin Pract 
2007;78:398–404.
 26. Tam WH, Yang XL, Chan JCN, et al. Progression to impaired glucose 
regulation, diabetes and metabolic syndrome in Chinese women 
with a past history of gestational diabetes. Diabetes Metab Res Rev 
2007;23:485–9.
 27. Rivero K, Portal VL, Vieira M, et al. Prevalence of the impaired 
glucose metabolism and its association with risk factors for coronary 
artery disease in women with gestational diabetes. Diabetes Res Clin 
Pract 2008;79:433–7.
 28. Noctor E, Crowe C, Carmody LA, et al. ATLANTIC- DIP: prevalence 
of metabolic syndrome and insulin resistance in women with 
previous gestational diabetes mellitus by international association 
of diabetes in pregnancy study groups criteria. Acta Diabetol 
2015;52:153–60.
 29. Peer N, Lombard C, Steyn K, et al. High prevalence of metabolic 
syndrome in the black population of Cape town: the cardiovascular 
risk in black South Africans (CRIBSA) study. Eur J Prev Cardiol 
2015;22:1036–42.
 30. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS 
Guidelines for the Management of Dyslipidaemias: The Task 
Force for the Management of Dyslipidaemias of the European 
Society of Cardiology (ESC) and European Atherosclerosis Society 
(EAS) Developed with the special contribution of the European 
Assocciation for Cardiovascular Prevention & Rehabilitation 
(EACPR). Atherosclerosis 2016;253:281–344.
 31. Peer N, Steyn K, Lombard C, et al. Rising diabetes prevalence 
among urban- dwelling black South Africans. PLoS One 
2012;7:e43336.
 32. Erasmus RT, Soita DJ, Hassan MS, et al. High prevalence of 
diabetes mellitus and metabolic syndrome in a South African 
coloured population: baseline data of a study in Bellville, Cape town. 
S Afr Med J 2012;102:841–4.
 33. Jennings CL, Lambert EV, Collins M, et al. Determinants of insulin- 
resistant phenotypes in normal- weight and obese black African 
women. Obesity 2008;16:1602–9.
 34. Nehring I, Chmitorz A, Reulen H, et al. Gestational diabetes predicts 
the risk of childhood overweight and abdominal circumference 
independent of maternal obesity. Diabet Med 2013;30:1449–56.
 35. Venkataraman H, Sattar N, Saravanan P. Postnatal testing following 
gestational diabetes: time to replace the oral glucose tolerance test? 
Lancet Diabetes Endocrinol 2015;3:754–6.
 36. Gradidge PJ- L, Crowther NJ. Review: metabolic syndrome in black 
South African women. Ethn Dis 2017;27:189–200.
 37. Gupta Y, Kapoor D, Desai A, et al. Conversion of gestational 
diabetes mellitus to future Type 2 diabetes mellitus and the 
predictive value of HbA
1c in an Indian cohort. Diabet Med 
2017;34:37–43.
 38. Liu Z- Y, Zhao J- J, Gao L- L, et al. Glucose screening within six 
months postpartum among Chinese mothers with a history of 
gestational diabetes mellitus: a prospective cohort study. BMC 
Pregnancy Childbirth 2019;19:134.
 39. Helsinki WEU. Do. World Medical association Declaration of Helsinki. 
Fortaleza, Brazil, 2013.
 o
n
 April 8, 2020 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000740 on 27 November 2019. Downloaded from 
